Ask AI
ProCE Banner Activity

Precision Pathways in RCC: Experts Discuss Key HCP Questions

Clinical Thought

In this commentary, experts address questions on the latest clinical developments in RCC and guideline updates focusing on immunotherapy and targeted therapy advances in the personalization of care of patients with RCC.

Released: July 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This educational activity is supported by medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck Sharp & Dohme LLC.

AVEO Pharmaceuticals, Inc.

Bristol Myers Squibb

Eisai Inc.

Exelixis, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This activity is for oncologists, advanced practitioners, nurse practitioners, clinical nurse specialists, pharmacists, and other healthcare professionals caring for patients with renal cell carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Stratify RCC patients’ benefit likelihood from IO- or targeted regimens based on validated clinical, molecular, and tumor microenvironment biomarkers as well as traditional risk assessment 

  • Plan patient-centric first- and subsequent-line therapy for advanced/metastatic RCC using up-to-date guidelines, prior therapy history, evolving biomarker insights, and practical administration considerations

  • Manage adverse events across all approved and emerging systemic RCC regimens, considering regimen-specific toxicity, patient comorbidities, and optimal supportive care strategies

  • Evaluate current and emerging data from key clinical trials and real-world evidence for new targeted, immunotherapy, and cellular therapy strategies in both clear cell and non-clear cell RCC, and advocate for clinical trial participation where appropriate

Financial Disclosures

Primary Author

Bradley A. McGregor, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Daiichi Sankyo, Eisai, Exelixis, Gilead, Merck, Pfizer; researcher: Arcus, Bayer.

Brian I. Rini, MD, FASCO: consultant/advisor/speaker: AstraZeneca, Aveo, Bristol Myers Squibb, Eisai, Exelixis, Formedics, Johnson & Johnson, Merck, Pfizer, Xencor; researcher: Adela, Arcus, AstraZeneca, Aveo, Bristol Myers Squibb, Daiichi Sankyo, Deciphera, Exelixis, Genentech, Gilead, HiberCell, Incyte, Janssen, Merck, Pfizer, Point Biopharma, Regeneron, Surface Oncology, Tempus.

Karine Tawagi, MD: consultant/advisor/speaker: AstraZeneca, Cardinal Health, DAVA Oncology, Exelixis, Johnson & Johnson, Pfizer, Stemline.